Other Endocrine Nutritional & Metabolic O.R. Procedures DRG Reimbursement

DRG 628 encompasses other endocrine, nutritional, and metabolic operating room procedures with a Major Complication or Comorbidity, covering complex surgical and perioperative situations that increase resource use. This Diagnosis-Related Group is important for inpatient reimbursement because the Major Complication or Comorbidity designation raises payment to compensate for higher expected costs and longer hospital stays.

DRG 628 Overview

DRG 628 covers inpatient admissions for other endocrine, nutritional, and metabolic operations performed in an operating room setting when a Major Complication or Comorbidity is present. Typical cases include complex endocrine surgeries or metabolic procedure care with significant additional diagnoses that increase resource use and length of stay. This Diagnosis-Related Group matters for Medicare payment because the presence of a Major Complication or Comorbidity elevates payment relative to lower-severity groups, reflecting higher expected costs. Clear capture of principal procedures and coexisting serious conditions drives appropriate reimbursement under Medicare.

Acute perioperative metabolic optimization studies: randomized or cohort studies assessing interventions to stabilize endocrine and metabolic derangements in patients undergoing OR procedures for endocrine, nutritional, or metabolic disorders (for example, perioperative glycemic control protocols, steroid stress-dose strategies, or electrolyte and nutrition management bundles). These trials enroll inpatients with acute surgical indications such as complicated thyroid or parathyroid operations, adrenal procedures, or metabolic surgery complications, focusing on short-term outcomes like perioperative morbidity, length of stay, and rates of metabolic crises. Results are directly relevant to hospital clinicians and payers because effective perioperative protocols can reduce costly ICU stays, complications coded as MCC, and readmissions associated with metabolic instability.
Comparative effectiveness studies of surgical versus minimally invasive or staged approaches in complex endocrine procedures: pragmatic trials or registry-based comparative studies evaluating clinical outcomes, complication rates, and resource utilization between open operations, laparoscopic/robotic procedures, and hybrid or staged interventions for complex endocrine or nutritional surgical indications. These studies target heterogeneous inpatient populations with comorbid endocrine or metabolic disease (for example, patients with severe obesity-related metabolic dysfunction, refractory hyperparathyroidism, or hormonally active adrenal tumors) to determine which approach yields the best balance of clinical benefit and hospital resource use. Findings inform procedural selection, coding and case-mix assignment, and payer decisions by clarifying which operative strategies may lower per-case costs, reduce MCC occurrences, and improve recovery trajectories.
Post-discharge outcomes and transitional care trials focusing on metabolic complication prevention: longitudinal cohort studies or randomized care-management trials testing discharge bundles, remote monitoring, or structured endocrine follow-up to prevent readmissions and late complications in patients discharged after O.R. procedures with major complications. These studies enroll high-risk inpatient cohorts (patients who experienced MCC-level complications, prolonged nutrition support, or significant electrolyte/hormonal derangements) to measure readmission rates, functional status, long-term metabolic control, and total cost of care over 30–180 days. This research is important to providers and payers because reducing post-discharge adverse events and downstream utilization can meaningfully lower overall expenditures for cases assigned to this DRG while improving quality metrics and patient safety.

Acute perioperative metabolic optimization studies: randomized or cohort studies assessing interventions to stabilize endocrine and metabolic derangements in patients undergoing OR procedures for endocrine, nutritional, or metabolic disorders (for example, perioperative glycemic control protocols, steroid stress-dose strategies, or electrolyte and nutrition management bundles). These trials enroll inpatients with acute surgical indications such as complicated thyroid or parathyroid operations, adrenal procedures, or metabolic surgery complications, focusing on short-term outcomes like perioperative morbidity, length of stay, and rates of metabolic crises. Results are directly relevant to hospital clinicians and payers because effective perioperative protocols can reduce costly ICU stays, complications coded as MCC, and readmissions associated with metabolic instability.
Comparative effectiveness studies of surgical versus minimally invasive or staged approaches in complex endocrine procedures: pragmatic trials or registry-based comparative studies evaluating clinical outcomes, complication rates, and resource utilization between open operations, laparoscopic/robotic procedures, and hybrid or staged interventions for complex endocrine or nutritional surgical indications. These studies target heterogeneous inpatient populations with comorbid endocrine or metabolic disease (for example, patients with severe obesity-related metabolic dysfunction, refractory hyperparathyroidism, or hormonally active adrenal tumors) to determine which approach yields the best balance of clinical benefit and hospital resource use. Findings inform procedural selection, coding and case-mix assignment, and payer decisions by clarifying which operative strategies may lower per-case costs, reduce MCC occurrences, and improve recovery trajectories.
Post-discharge outcomes and transitional care trials focusing on metabolic complication prevention: longitudinal cohort studies or randomized care-management trials testing discharge bundles, remote monitoring, or structured endocrine follow-up to prevent readmissions and late complications in patients discharged after O.R. procedures with major complications. These studies enroll high-risk inpatient cohorts (patients who experienced MCC-level complications, prolonged nutrition support, or significant electrolyte/hormonal derangements) to measure readmission rates, functional status, long-term metabolic control, and total cost of care over 30–180 days. This research is important to providers and payers because reducing post-discharge adverse events and downstream utilization can meaningfully lower overall expenditures for cases assigned to this DRG while improving quality metrics and patient safety.

OpenPayer

Summary & Overview

Other Endocrine, Nutritional and Metabolic O.R. Procedures with MCC: Inpatient Reimbursement Overview

DRG 628 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes